Vnitr Lek 2006, 52(7-8):736-741

Pathogenesis, diagnostics and therapy of gout

M. ®urek
III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil ©čudla, CSc.

Gout refers to heterogeneous group of metabolic diseases characterized by production of deposits of sodium urate crystals in tissues. Gout manifests as acute gouty arthritis with classic clinical picture, or as chronic gouty arthropathy with periarticular and subcutaneous deposits of sodium urate crystals, i.e. tophi. As for kidney, gout is manifested as acute or chronic gouty nephropathy and urolithiasis. These manifestations occur separately or they are combined. Hyperuricemia of primary gout is caused rather by impaired renal secretion than overproduction of uric acid. Secondary hyperuricemia is associated with many pathological conditions; it is also connected with the use of various medicaments. Pathogenesis of gouty arthritis is critically influenced by sodium urate crystals and inflammatory processes they induce. Hyperuricemia is part of metabolic syndrome X which is associated with unanswered question of the relationship between uric acid and atherosclerosis. Although gouty arthritis is the most frequent inflammatory disease of joints in men over 50 years of age, it is often diagnosed and treated inadequately. On that account, the indication of long-term hypouricemic therapy should be always based on the following criteria: secondary causes of hyperuricemia have to be excluded first; frequency of gout attacks and the risk of their recurrence should be taken into consideration; then it is necessary to search for renal manifestations of gout; and last but not least, we should check whether there are any associated diseases classified in metabolic syndrome X.

Keywords: gout; hyperuricemia; gouty arthritis; chronic tophaceous gout; asymptomatic hyperuricaemia; therapy of gout

Received: March 8, 2006; Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®urek M. Pathogenesis, diagnostics and therapy of gout. Vnitr Lek. 2006;52(7-8):736-741.
Download citation

References

  1. Ghei M, Mihailescu M, Levinson J et al. Pathogenisis of hyperuricemia. Recent advances. Curr Rheumatol Rep 2002; 4: 270-274. Go to original source... Go to PubMed...
  2. Campion EW, Glynn RJ, deLabry LO. Asymptomatic hyperuricemia: the risks and consequences. Am J Med 1987; 82: 421-426. Go to original source... Go to PubMed...
  3. Harris E, Budd R, Firestein G et al. Kelley's Textbook of Rheumatology. 7. ed. Philadelphia: WB Saunders 2004: 1402-1425.
  4. Fam AG, Schumacher HR Jr, Clayburne G et al. A comparison of five preparations of synthetic monosodium urate monohydrate crystals. J Rheumatol 1992; 19: 780-787. Go to PubMed...
  5. Stankovic A, Front P, Barbara A et al. Tophus-derived monosodium urate monohydrate crystals are biologically much more active than synthetic counterpart. Rheumatol Int 1991; 10: 221-226. Go to original source... Go to PubMed...
  6. Chapman PT, Yarwood H, Harrison AA et al Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1977; 40: 955-965. Go to original source... Go to PubMed...
  7. Roberge CJ, Brassi J, de Medicis R et al. Crystal-neutrophil interactions lead to interleukin-synthesis. Agents Actions 1994; 34: 38-41. Go to original source... Go to PubMed...
  8. Tudan C, Fong D, Duronio V et al. The inhibition of spontaneous and tumor necrosis factor-α induced neutrophil apoptosis by crystals of calcium pyrophosphate dihydrate and monosodium urate monohydrate. J Rheumatol 2000; 27: 2463-2472. Go to PubMed...
  9. Landis RC, Yagnik DR, Florey O et al. Safe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophages. Arthritis Rheum 2002; 46: 3026-3033. Go to original source... Go to PubMed...
  10. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2288-2297. Go to original source... Go to PubMed...
  11. Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13. Go to original source... Go to PubMed...
  12. Bettencourt P, Ferreira A, Dias P et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail 2000; 6: 306-313. Go to original source... Go to PubMed...
  13. Bigger JT, Heller CA, Wenger TL et al. Risk stratification after acute myocardial infarction. Am J Cardiol 1978; 42: 202-210. Go to original source... Go to PubMed...
  14. Pavelka K. Is diagnosis and therapy of gout a simple matter? Vnitř Lék 1993; 39: 1073-1079. Go to PubMed...
  15. Hochberg MC, Silman AJ, Smolen JS. Rheumatology. 3. ed. Pittsburg: Mosby 2003: 1920-1921.
  16. Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11: 441-445. Go to original source... Go to PubMed...
  17. Fernandez C, Moguera R, Gonzalez JA et al. Treatment of acute attacks of gout with a small dose of intraarticular triameenalone acetonide. J Rheumatol 1999; 26: 2285-2286. Go to PubMed...
  18. Iacobuzio-Donahue CA, Lee EL, Abraham SC et al. Colchicine toxicity. distinct morphologic findings in gastrointestinal biopsies. Am J Surg Path 2001; 25: 1067-1073. Go to original source... Go to PubMed...
  19. Scott JT, Higgens CS. Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 1992; 51: 259-261. Go to original source... Go to PubMed...
  20. Eastmond CJ, Garton M, Robins S et al. The effects of alcoholic beverages on urate metabolism in gout sufferers. Br J Rheumatol 1995; 34: 756-759. Go to original source... Go to PubMed...
  21. McCarthy GM, Barthelemy CR, Veum JA et al. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991; 34: 1489-1494. Go to original source... Go to PubMed...
  22. Yu TF. The efficacy of colchicine prophylaxis in articular gout - a reappraisal after 20 years. Semin Arthritis Rheum 1982; 12: 256-263. Go to original source... Go to PubMed...
  23. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87. Go to original source... Go to PubMed...
  24. Pavelka K. Dna (arthritis urica). In: Pavelka K, Rovenský J. Klinická revmatologie. Praha: Galén 2003: 447-458.
  25. Pavelka K. Terapie dny. In: Pavelka K et al. Farmakoterapie revmatických onemocnění. Praha: Grada 2005: 349-350.
  26. Wallace SI, Robinson H, Masi AT et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1997; 20: 895-900. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.